Dexmethylphenidate, d-MPH (Focalin) is a new methylphenidate (d,l-MPH; MPH) formulation of the active enantiomer only. A variety of methylphenidate products are available but only dexmethylphenidate is the purified active enantiomer.
Drug Criteria & Outcomes: Drug evaluation: Dexmethylphenidate hydrochloride tablets (Focalin)
Drug Criteria & Outcomes
Drug evaluation: Dexmethylphenidate hydrochloride tablets (Focalin)
Part 1: Mechanism of Action, Pharmacokinetics, Indication, Dosage, Contraindications, Drug Interactions, Adverse Reactions, Warnings and Precautions
By Emily K Pauli, BS, BMS, PharmD Candidate
Harrison School of Pharmacy
Auburn (AL) University
Dexmethylphenidate, d-MPH (Focalin) is a new methylphenidate (d,l-MPH; MPH) formulation of the active enantiomer only. A variety of methylphenidate products are available but only dexmethylphenidate is the purified active enantiomer.
Mechanism of action
Proposed: Dexmethylphenidate (d-MPH) is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine and increases the release of monoamines. The actual mechanism of action is not known.
Pharmacokinetics
- The pharmacokinetic differences (if any) between d-MPH and d,l-MPH are clinically insignificant.
- Absorption
— Well absorbed (both d-MPH and d,l-MPH).
— Time to peak in the fasted state is 1-1.5 hours post-dose for d-MPH; 2 hours for the racemic products (d,lMPH).
— Food delays the time to peak by approximately 1.5 hours but does not affect the Cmax or AUC for d-MPH or d,l-MPH.
- Distribution
— Plasma levels decline exponentially following oral administration.
— No data are provided regarding distribution of d-MPH.
— Protein binding of racemic methylphenidate is minimal (15.2%).
— Volume of distribution for d,l-MPH is 1.1-6 L/kg.
- Metabolism
De-esterification to an inactive metabolite (d-ritalinic acid) for both d-MPH and d,l-MPH.
- Excretion
— Elimination half-life is 2.2 hours for d-MPH and d,l-MPH.
— d-MPH and d,l-MPH do not inhibit cytochrome P450 isozymes.
— Primarily excreted in the urine (80%) as the inactive metabolite.
— Specific renal excretion data for d-MPH are unavailable. However, approximately 90% of an oral dose of d,l-MPH appears in the urine, mainly as ritalinic acid (about 80%); less than 1% appears as unchanged methylphenidate.
Indication
- d-MPH
— Treatment of attention deficit hyperactivity disorder (ADHD).
— Efficacy established in clinical trials in patients 6-17 years of age.
— Long-term use (greater than six weeks) has not been evaluated with d-MPH.
- d,l-MPH
— Treatment of ADHD in both children and adults.
— Narcolepsy. — Disease-related fatigue
Dosage
- d-MPH
— Administered twice daily and at least four hours apart, irrespective of food.
— Thirty to 45 minutes prior to a meal; morning and noontime is recommended.
— Dosing is individualized to the patient and based on response.
— Dosing is for children 6-17 years old; not established in adults and children younger than 6 years of age.
— Treatment naïve: Initiate at 5 mg/day (2.5 mg twice daily); weekly adjustment of 2.5-5 mg daily to a maximum dose of 20 mg/day (10 mg twice daily).
— Treatment non-naïve: Initiate d-MPH at half the dose of other methylphenidate products; weekly adjustments of 2.5-5 mg daily to a maximum of 20 mg/day (10 mg twice daily).
— When changing from d-MPH tablets to d-MPH XR capsules, patients may be switched to the same daily dose using d-MPH XR (maximum dose: 20 mg/day).
- Racemic methylphenidate (d,l-MPH)
— Administered twice daily and at least four hours apart, irrespective of food.
— Thirty to 45 minutes prior to a meal; morning and noontime is recommended.
— Dosing is individualized to the patient and based on response.
Adult
Immediate-release
- 10-60 mg daily; average dose is 20-30 mg daily; administer 2-3 times daily, preferably 30-45 minutes before meals.
Extended-release
- Starting dose of Concerta extended-release tablet for new patients is 18 mg once a day in the morning; adjust weekly in 18-mg increments to a maximum of 54 mg per day. Patients converting from immediate-release (IR) or sustained-release (SR) methylphenidate may follow the dosage conversion recommendation shown in Table 1.
- For methylphenidate extended-release capsules (Metadate CD) the starting dose is 20 mg once daily in the morning before breakfast; increase by 20 mg at weekly intervals to a maximum dose of 60 mg/day taken once daily in the morning.
Pediatric
Immediate-release
- Usual dose is 5 mg twice daily; increased at weekly intervals by 5-10 mg; maximum recommended dose is 60 mg.
Extended-release
- For methylphenidate extended-release capsules, the starting dose is 20 mg once daily in the morning before breakfast; increased by 20 mg at weekly intervals to a maximum dose of 60 mg/day taken once daily in the morning.
Dosage forms of comparable methylphenidate products
- Immediate-release
— Dexmethylphenidate (Focalin)
— Ritalin HCl
— Methylphenidate HCl
— Methylin
- Extended-release
— Ritalin LA/Ritalin SR
— Metadate CD/Metadate ER
— Concerta
— Methylin ER
— Methylphenidate ER
— Dexmethylphenidate (Focalin XR)
Contraindications
- Same contraindications for d-MPH and d,l-MPH
— Agitation (patients with marked anxiety, tension, and agitation): d-MPH and d,l-MPH may aggravate the symptoms.
— Hypersensitivity to any methylphenidate product or component of d-MPH.
— Glaucoma. — Tics: Motor tics, family history, or diagnosis of Tourette’s syndrome; in rare cases MPH has caused Tourette’s syndrome.
— Current or recent (within 14 days) treatment with monoamine oxidase inhibitors: Hypertensive crisis may result.
Drug interactions (based on d,l-MPH)
- Same interactions and frequency of interactions for d-MPH and d,l-MPH
— May decrease the effects of antihypertensive treatments.
— May inhibit metabolism of coumarins, anticonvulsants (phenobarbital, phenytoin, primidone), tricyclic antidepressants, selective serotonin reuptake inhibitors; lower doses of these drugs.
Adverse reactions
- Same for d-MPH and d,l-MPH
— Paradoxical aggravation: Reduce the dose or discontinue d-MPH.
— The most common reasons (1% for each) for discontinuation were: motor or vocal tics, anorexia, insomnia, and tachycardia.
— Adverse events with an incidence of 5% or more include: abdominal pain (15%), fever (5%), anorexia (6%), and nausea (9%)
— Adverse events reported with use of other MPH products include: angina, arrhythmias, dizziness, headache, drowsiness, dyskinesia, psychosis, changes in blood pressure, cerebral arteriti, or occlusion.
— Although no established casual relationship has been established, the following events have been reported: leukopenia, anemia, elevated liver associated enzymes, hepatic coma, transient depression, alopecia, and neuroleptic malignant syndrome.
Warnings and precautions
- Unless otherwise noted, these are the same for both d-MPH and d,l-MPH.
- Depression.
- Fatigue.
- Long-term use and growth suppression: Safety of long-term use (more than six weeks) has not been established with d-MPH
— Still controversial that d,l-MPH MAY cause growth suppression after long-term treatment.
- May exacerbate psychosis.
- May lower the seizure threshold: Discontinue if seizures occur.
- Use cautiously in hypertensive patients or in patients with conditions that increase heart rate or blood pressure (heart failure, myocardial infarction, hyperthyroidism).
- Give cautiously in patients with a history of substance abuse or dependence.
- Pregnancy Category C.
- Unknown if excreted in breast milk.
- Safety and efficacy is not established in children younger than 6 years of age.
Look-/sound-alike drugs for dexmethylphenidate (Focalin):
— Methylin, Ritalin
— Metadate, methylphenidate
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.